Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Epigenetic Therapy Testing of a Family of Novel DNA Methyl Transferase Inhibitors
AmorChem Canada flag Canada
Abstract ID:
Four novel DNA methyl transferase inhibitors (DNMTIs) are being developed and tested. DNMTIs are currently used to treat patients with a form of leukemia called myelodysplastic syndrome (MDS)....
Contact John Clement
Participants
You
Email me a copy of this message

DNA methylation (and demethylation) is one of several regulators of gene transcription. Aberrant DNA methylation is an epigenetic mechanism that can inactivate the expression of certain genes involved in the suppression of tumorigenesis such as tumor suppressor genes, genes that suppress apoptosis, metastasis and angiogenesis, genes that repair DNA and genes that express tumor-associated antigens.

Four novel DNA methyl transferase inhibitors (DNMTIs) have been designed, synthesized and are being tested. Our lead nucleoside is different from the approved DNMTIs, such that it inhibits DNMT in both solid tumor and hematologic tumor cell lines and has shown activity in cell lines resistant to 5-azadC. It is more active as a DNMTI and less cytotoxic than 5-azaC.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
Out-licensing or collaboration
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development PRECLINICAL
CORPORATION